FDA Should Reassess Patient Information Sheet Proposal, NCPIE Says
Executive Summary
FDA should rethink its proposal for agency-issued patient information sheets, National Council on Patient Information & Education Exec VP Ray Bullman said at a recent hearing on drug safety communications
You may also be interested in...
Pharmacy Leaflets Become Focus For Patient Safety; IoM, FDA Finalize Standards
Producers of consumer medication information leaflets are hoping that FDA provides them with more time to come into compliance with standards for usefulness, even as an Institute of Medicine report is emphasizing the need for quality in the materials
Pharmacy Leaflets Become Focus For Patient Safety; IoM, FDA Finalize Standards
Producers of consumer medication information leaflets are hoping that FDA provides them with more time to come into compliance with standards for usefulness, even as an Institute of Medicine report is emphasizing the need for quality in the materials
FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question
Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C